Management of A Dental Patient on Bisphosphonates: All That A Dentists Needs to Know

A.GAUTHAM 1, DEEPAK BABY 2, BABITHA THOMAS 3, ISMAIL P.M 4

1 Post Graduate student, Dept. of Conservative Dentistry & Endodontics, PSM Dental College, Akkikavu, Thrissur, Kerala.
2 Professor and Head of the Department, Dept. of Conservative Dentistry & Endodontics, PSM Dental College, Akkikavu, Thrissur, Kerala.
3 Post Graduate student, Dept. of Conservative Dentistry & Endodontics, PSM Dental College, Akkikavu, Thrissur, Kerala.
4 Post Graduate student, Dept. of Conservative Dentistry & Endodontics, PSM Dental College, Akkikavu, Thrissur, Kerala.

Abstract: The aim of this review is to give an update on the protocols to be followed by the dentists for dental procedures for patients on bisphosphonate therapy. Presently there is an increasing prevalence of patients receiving bisphosphonate therapy. This review has included the pathological effects on alveolar bone, epithelium, variations in healing time, angiogenesis, and the risk factors associated with Bisphosphonate related osteonecrosis of the jaw (BRONJ) development. The consensus management protocols as recommended by experts is presented comprehensively. It is envisaged that dental practitioners should have a better understanding of bisphosphonate therapy and the complications associated with various dental procedures so as to enable them to render care with confidence and to improve the quality of life of their patients on bisphosphonate therapy.

Key words: Bisphosphonates, BRONJ, tooth extraction, tooth implants, prevention of BRONJ

I. Introduction

With increasing life expectancy, dentists come across many patients with dental problems who take bisphosphonate therapy (BP). BP are group of drugs which are used in skeletal conditions like osteoporosis, osteopenia, Paget’s disease, multiple myeloma and metastatic cancer. Patients on BP, when they undergo tooth extraction, placement of implants, maxillofacial surgery and those with periodontal diseases are more prone to develop Bisphosphonate related osteonecrosis of the jaw (BRONJ). This is a serious problem both clinically as well as legally and hence it is imperative for all the dentists to know the pathological effect of BP on oral cavity and treatment protocols in a patient on BP.

II. Bisphosphonates in brief

Bisphosphonates (BP) are stable structural analogy of pyrophoshates and suppress the activity of osteoclasts which leads to reduced bone resorption which are deposited in bone surface in the first few minutes of uptake. The unbound BP are removed renally. BP can be classified into 3 generations:
- First generation: They are non-nitrogen containing BP. Etidronate, Clodronate and tiludronate
- Second generation: They are alkyl amino nitrogen containing BP. Alendronate, Ibandronate and Pamidronate
- Third generation: They are heterocyclic nitrogen containing BP. Minodronic acid Risdronate and Zoledronic acid.

Side effects of BP: Nausea, epigastric pain, oesophagitis and gastric ulcer. Myalgia, arthralgia, low grade fever, headache, bone pain due to acute phase response occur during the first 24 hours after IV BP. Atrial fibrillation has also been reported.

Oesophageal and gastric cancer, Uveitis, Scleritis and Orbital inflammatory diseases, Atypical proximal femoral fracture has also been reported after long duration of BP.
III. Pathophysiology of the effects of BP in oral cavity

Effect of BP on alveolar bone:
After the administration of both oral and IV BP, a large amount of the drug is deposited in the maxillofacial bones. In the jaw, the bone undergoes high turnover modelling to maintain biomechanical competence and this is accelerated after tooth extraction. The greater the turnover of the bone, the greater the amount of BP deposited. The mandibular alveolar bone turnover rate is higher when compared to the other bones in the maxillofacial region and this explains the increased incidence of BRONJ in the mandibular molar areas. The BP deposited decreases osteoblast and osteoclast recruitment. There is a decrease in osteoclast adhesion, inhibition of osteoclast differentiation, osteoclast apoptosis, empty lacunae, the absence of matrix and presence of unorganised fibrous structures. This decreases bone resorption and reduces the new bone multilayer units. This induces bone matrix necrosis. The alveolar bone matrix loses the required regenerative ability following tooth extraction, thereby predisposing the bone to necrosis when trauma is applied.

Effect of BP on oral epithelium:
Dental extraction or other intraoral trauma release BPs locally from the adjacent injured bone, thereby exposing oral epithelial cells to the adverse effects of BPs. BPs are directly toxic to epithelial cells and inhibit the proliferation of adjacent epithelial cells. BPs also reduces sacroglycan and integrin transmembrane proteins, which are necessary for cell and cell matrix adhesion. This results in delay of soft tissue healing. BPs decreases P63 positive basal epithelial progenitor, which is necessary for initiation of epithelial stratification during the development and maintenance of basal keratinocytes. BPs block collagen expression by oral fibroblasts and cause delay in oral soft tissue healing. Apoptosis of epithelial cells is also increased by the BPs.

Effect of BP on angiogenesis:
The major cause of delay in healing after tooth extraction is due to ischemic changes in the vascular bed. BP inhibits angiogenesis by interacting with vascular endothelial growth factor (VEGF) and inhibits endothelial cell function leading to avascular necrosis. Low doses of BP inhibit the differentiation of endothelial progenitor cells, while high doses induce apoptosis of these cells. BP decreases the serum level of VEGF ad other cytokines like IL-17, which are involved in angiogenesis. Endothelial cell proliferation and pro-angiogenic factors such as fibroblast growth factor 2 (FGF2) are inhibited.

Infection, inflammation and wound healing in patients on BP:
Prolonged exposure of the underlying bone after tooth extraction in patients on BP, expose to oral microorganisms, like Actinomyces, Eibonella and Moraxella, which are common organisms implicated in BRONJ. Pre-existing inflammatory dental disease such as periodontitis and periapical pathology aggravates the colonisation of bacteria and increases the incidence of BRONJ. Teeth that are extracted because of pre-existing periodontal or periapical disease are associated with tooth infection and inflammation. Keratinocyte Growth Factor (KGF) in the gingival fibroblast play an important role in epithelial wound healing. Bacterial infection in periodontal diseases decrease KGF and cause delay in wound healing. Wound healing is longer in patients receiving BP. The mean healing time for patients with BP is 5 weeks, compared to 2 weeks without BP. Corticosteroids suppress osteoblasts, increase apoptosis of osteoclasts, osteoblasts and osteocytes and increased bioavailability of concurrently used BPs and increase the risk of BRONJ.

IV. BP and BRONJ
BRONJ (as defined by the American Society For Bone and Mineral Research) is an exposed area of bone in the upper and lower jaw, in the maxillofacial region, which does not resolve within 8 weeks afterdiagnosis in a patient taking BP, who has not received radiation therapy in the maxillofacial region. BP gets highly concentrated in jaw because of high viscosity. BP has an antiangiogenic effect and hence aggravate ischemia. The cytotoxic effect of BP on osteoclasts and periodontal ligament cells suppress bone marrow turnover.

Prevalence: 0 – 28% in patients receiving nitrogen containing BP 4% chances on patients on oral BP
Dental extraction and trauma trigger BRONJ in 64%
Periodontitis accompanies 84% of BRONJ
The incidence of BRONJ in patients with malignant diseases on BP range from about 1 to 21%
Mandible is more affected than the maxilla (2:1 ratio)
V. Clinical signs, symptoms and treatment
The traditional sign is exposed necrotic bone. The symptoms include pain in the tooth, bone purulence, swelling, fistula and sinus in the affected jaw, teeth mobility, trismus, nonhealing extraction sockets, ulcer in soft tissue and gross deformation in lower jaw. The American Association of Oral and Faciomaxillary Surgeons has staged BRONJ.

- **At risk category:** Here there is no exposed necrotic bone. These patients do not require treatment. Patient should be educated regarding the risks of BRONJ. Periodic follow-up and radiological check-ups should be done.
- **Stage 0:** Non-specific clinical findings and symptoms like mandibular pain, with no clinical evidence of exposed bone. Treatment is mainly medical treatment and management of local risk factors. Medical treatment include antiseptic, analgesic, antibiotics and antiphlogistic treatment. Low level laser therapy can help. A careful follow up is necessary.
- **Stage 1:** Exposed/ necrotic bone in asymptomatic patients with no evidence of infection. The exposed and necrotic bone or fistulae should be rinsed with antiseptic fluids and cover with adhesive paste 3 times a day. If there is no healing after 8 weeks, surgical debridement should be done.
- **Stage 2:** Exposed/ necrotic bone associated with evidence of infection, such as pain and erythema in the area of exposed bone, with or without pus drainage. Treatment is conservative surgical debridement after 2 weeks of antibiotics and antiphlogistic treatment.
- **Stage 3:** Exposed/ necrotic bone with pain, infection along with any one of the following – pathological fracture, extraoral fistula or osteolysis extending to the inferior border or sinus floor. Treatment is marginal or segmental osteotomies. Invasive surgery must be done only if it would improve the quality of patient’s life. If the general condition of the patient is poor for invasive surgery or if patient rejects surgery, conservative approach to control symptoms and osteonecrosis progression must be done.

VI. Risk categorization of patients in BP
- **Low risk patients:** Patients on oral BP for less than 4 years with no other co-morbid conditions.
- **Moderate risk patients:** Patients on oral BP for more than 4 years, smokers, patients with very poor oral hygiene, anaemia and diabetes. Concomitant corticosteroids both oral and IV. Patients taking 7.5 mg of prednisolone daily for more than 3 months are at increased risk. Patients on antiangiogenic drugs like Axitinib and Bevacizumab.
- **High risk patients:** Patients on treatment for cancer, regardless of the route of BP administrations should be considered as high risk. Those with previous history of BRONJ and those on second and third generation BP are at very high risk. Patients on single nucleotide polymorphism in the RBMS3 gene (genetic predisposition) are more prone for BRONJ. Age greater than 65 years and patients with Tori and other bony exostosis are also considered as high risk.

VII. Prevention protocol for BRONJ on patients on BP
- Establishment of good oral hygiene before dental procedures.
- Extraction of non-restorable teeth and teeth with poor prognosis before initiation of BP.
- BP holiday: In high risk cases, a three months drug withdrawal prior to the procedure and cessation of the drugs until wound healing has been advocated.
- Pre-procedure antibiotics in moderate and high-risk cases.
- Cessation or reduction of corticosteroids.
- Active treatment of oral infection if any.

VIII. Counselling for patients before taken for procedure
Dentist should inform the following to the patients on oral bisphosphonates before the procedure:
- There is a very low risk of developing BRONJ after the procedure. The approximate risk is estimated at 0.7 cases per 100000 persons – year exposure.
- There are ways to minimize the risk, but not to eliminate the already low risk.
- Good oral hygiene along with regular dental care is the best way to lower the risk.
- There are no diagnostic techniques to identify those at increased risk of developing BRONJ.
- The patient should be informed about the dental treatment needed, alternative treatments, how any treatment relates to the risk of BRONJ, other risks associated with various treatment options and the risk of foregoing treatment, even temporarily.
- The patient should be encouraged to consult with his or her treating physician about other health risks associated with the procedure.

DOI: 10.9790/0853-1908162129 www.iosrjournal.org 23 | Page
Patient should have all their doubt clarified to the maximum extent possible before the procedure. The dentist must document the discussion of risks, benefits and treatment options with patient and obtain written acknowledgement of the discussion and get written consent for the chosen course of treatment.

IX. BP and its implication in endodontics

In endodontic infection, microorganisms first invade the root canal and this leads to pulpal necrosis. Inflammation then spreads to the periapical tissue through the apical foramen. When macrophages are exposed to inflammatory stimuli, they secrete cytokines like TNF-α, IL-1, IL-6, IL-8 and IL-12. The degradation proteins like collagenase and proteinase also stimulate macrophages. Further, bacterial endotoxins activate the compliment system. The compliment components interact with variety of receptors on macrophages, leading to the modulation of cytokine production and inflammatory response. This provoke the differentiation of macrophages to osteoclasts. Osteoclasts increase bone resorption and hence inhibit the resorption of bone by osteoclasts and inhibits bone remodelling. (FIGURE 1)

Also they interfere with healing of periapical lesions. BP delay healing of extraction sockets. This predisposes to infection and may lead to BRONJ. Hence dental extraction could be delayed or even avoided by performing root canal treatment. Root canal therapy eliminate infection and prevent from infiltration to periapical tissue. In a study, healing rate of periapical tissue taking BP and those without BP showed a healing rate of 73.5% and 81.6% respectively. In another study, effect of IV Zolendronate on the clinical and radiographic success of nonsurgical root canal treatment was studied. The results showed that patient who are on BP for more than 1 year has less success rate. RCT can trigger the process of BRONJ through soft tissue damage, especially during application of rubber dam, apical extrusion of debris during cleaning and shaping of root canal.

Patel and saberi described a case series of external cervical resorption in patient taking BP, where no other possible cause of resorption was present. Their findings are that acute phase response to amino containing BP initiates external cervical resorption in teeth. Animal studies show that the superficial application of Zolendronate and Alendronate reduce replacement root resorption in intentionally replanted teeth. Low dose of alendronate inhibits the receptor activation of nuclear factor Kappa Beta ligands [RANKL] of generated osteoclasts without cytotoxic influences. In open apex teeth with pulpal necrosis, the new concept of treatment is ‘revascularisation’. Here the root canal system is disinfect first. Then intracanal bleeding is induced through the apical foramen. This creates a suitable environment for endogenous mesenchymal stem cells to differentiate to several types of odontogenic cells and complete root canal maturity. Induction of intracanalicular bleeding trigger BRONJ. Hence the treatment of choice in this condition is apexification or apexogenesis.
Clinical recommendations in endodontic procedure:

- Endodontic treatment is preferable to surgical treatment if a tooth is salvageable.
- Any procedure should be started with Chlorhexidine mouthrinse for one minute. This reduces the number of microorganisms in the oral cavity and reduces the chances of bacteremia that may be present due to soft tissue trauma.
- BP has anti-angiogenic effects.
- Hence using anesthetic agents with vasoconstriction effects has to be avoided as it increases the risk of inadequate vascularisation.
- Rubber band application must be done with almost care to prevent soft tissue trauma.
- Aseptic environment should be ensured during the procedure.
- The tooth and rubber dam must be disinfected with a suitable disinfecting solution for 2 minutes.
- Manipulation beyond the apex should be avoided. Avoid patency of the apical foramen, which can increase the possibility of bacteremia from extruded debris. Hence it is recommended to use electronic apex locators during cleaning and shaping to maintain files at apical constriction and prevent it from apical extrusion.
- Nickel Titanium rotary systems are preferred. Avoid reciprocating systems during shaping of root canal due to more risk of extrusion of debris.
- Obtruration should be done with minimal risk of overfilling and overextension, to increase the efficiency of root canal treatment and reduce the possibility of periapical irritation.
- The cold lateral compaction technique is preferred over warm root filling techniques.
- The use of prophylactic antibiotics in patients on BP before a nonsurgical root canal treatment has remained a controversy. Patients who are on IV BP with necrotic pulps, oral BP for more than 3 years and several teeth requiring root canal treatment are preferably put on systemic antibiotics.
XI. Tooth extraction in a patient on BP

In low risk patients, extraction can be carried out, after getting informed and written consent from the patient explaining the risks. A thorough mouth wash with 0.12 to 0.2% chlorhexidine should be done before tooth extraction. The removal of tooth must be done with least trauma to the soft tissue. If the treatment plan involves the medullary bone and or periosteum involving multiple sextants, then the dentist should treat one sextant or one tooth at a time if possible. The dentist should allow a two months disease free follow up, treating the patients with antimicrobials, before other sextants are treated with similar therapy. Primary closure of extraction wound should not be considered a must\(^{80,81}\). Tooth extraction can be performed without the detachment of full thickness flaps, and the socket should be filled with absorbable gelatin sponge haemostatic including suture placement, so as to allow wound healing through secondary intention. If a sharp socket wall margin or intraradicular bone are observed, they should be reduced selectively without lifting the periosteum from bone. Surgical antibiotic prophylaxis is needed if needed only for selected patients. If antibiotic prophylaxis is needed, it is ideal to start on phenoxymethylpencillin 500 mg 4 times per day. If patient is penicillin allergic, doxycycline 100mg once daily is suitable. Metrodinizole 200mg 3 times a day can also be used in high risk patients. Oral antibiotics should be given one hour prior to the procedure. After extraction of tooth weekly review is mandatory. If there is debris in the socket, it has to be irrigated with saline or chlorhexidine only. Follow up is needed for 3 to 4 weeks for symptoms of BRONJ. Pain, fetor oris and bad taste are few presenting symptoms of post-extraction BRONJ.

In patients with medium risks, i.e., patients with associated risk factors, the risk factors have to be reduced and later tooth extraction must be done after getting informed consent.

In patients with high risks, first the patients must be assessed whether tooth extraction can be avoided. If tooth extraction can be avoided, other treatment modalities like endodontic treatment has to be considered. If tooth extraction is absolutely necessary, tooth extraction must be done after getting written consent, explaining all the risks of BRONJ, along with adjunctive treatment. Cancer patients receiving IV BP must receive plasma rich growth factors during tooth extraction to shorten healing time\(^{82}\). After tooth extraction, patient should be reviewed weekly for 3-4 weeks. If debris is present in the socket irrigate with saline or chlorhexidine only. If healing of the socket does not take place within 3-4 weeks, closely follow up for BRONJ. If the bone is exposed at 6-8 weeks, treatment for BRONJ has to started.

XII. Implant treatment for a patient on BP

Implant placement requires the preparation of osteotomy sites. Hence patients on BP requiring extensive implants and guided bone regeneration to augment the deficient alveolar ridge before implant placement are at increased risk of BRONJ. Hence dentist must first discuss with the patients about the risks, benefits and treatment alternatives available. Individuals who have been taking BP for less than four years and have no risk factors (low risk), there is no need for alteration of treatment plans\(^{83}\). For patients taking oral BP for less than four years and is taking corticosteroids or antiangiogenic drugs concomitantly (moderate risk), discontinuation of BP for two months prior to the surgery must be done (drug holiday). Treatment can be started after two months, but BP should be stared only after osseous healing has occurred. In high risk patients implants should be avoided.

A fully written informed consent must be obtained before the procedure. Patient should be stressed about the need of maintaining strict oral hygiene and any oral infection if present must be actively treated. Patients should be scheduled for a prophylaxis/Periodontal Maintenance Therapy (PMT) with the hygienist and oral rinse containing chlorhexidine to be stared at least one week prior to surgery. Assuming no Penicillin allergy, the patient should start on Augmentin 500 mg (4 times per day) starting 48 hours prior to scheduled surgery\(^{84}\).

As per Expert panel recommendations American Dental Association Council on Scientific Affairs, maintenance of the implants must follow accepted mechanical and pharmaceutical methods to prevent peri-implantitis. Patients must be kept under weekly follow-up. If features of peri-implantitis appears, active antibiotic treatment must be started. If peri-implantitis does not resolve with routine antibiotic therapy, surgical revision of soft tissues around the implants may be needed. If needed modest bone recontouring may be considered. If signs of infection still persist, initiation of treatment of BRONJ must be started.

XIII. Restorative dentistry and prosthodontics procedures in patients on BP

All routine restorative procedures can be carried out. There is no evidence that malocclusion or masticatory forces increase the risk of developing BRONJ. All prosthodontic appliances in patients taking an oral bisphosphonate should be adjusted for fit as needed.
If bone surgery are necessary, conservative surgical techniques with primary tissue closure must be considered. Chlorhexidine rinse should be started before the procedure and continued for two times per day for two months after surgery. Prophylactic antibiotics though not mandatory, clinicians can start it depending on the patients concomitant risk factors like prolonged BP, old age. use of steroids etc..

A patient on BP, with mild periodontal disease routine treatment can be carried out without modification, because BP is actually beneficial in modulating the host response for management of periodontal diseases. If the patient on BP is having destructive periodontal disease, they should receive appropriate non-surgical therapy along with prolonged phase of initial therapy. Inspite of these measures, if the disease doesn’t resolve, surgical treatment should be aimed primarily at obtaining access to root surface with modest bone recontouring. Guided bone regeneration or tissue regeneration must be considered, in view of fact that BP reduces vascularity of tissues.

A patient’s chances of developing BRONJ resulting from dental procedures is due to the compromisedhealing status of the hard and soft tissues of the jaws, and is also determined by significant risk factors, such as oral hygiene status, periodontal disease and systemic conditions. A thorough pre-operative risk assessment and clinical examination should be done before the procedure. The need for antibiotic prophylaxis must also be considered before the procedure. A complete and detailed discussion regarding the complication must be done with the patient and the patient’s physician. This will help the dental practitioner to judiciously plan and perform dental procedures on patients undergoing BP therapy.

Reference

Management Of A Dental Patient On Bisphosphonates: All That A Dentist Needs To Know


DOI: 10.9790/0853-1908162129 www.iosrjournal.org 28 | Page
Management Of A Dental Patient On Bisphosphonates: All That A Dentists Needs To Know


[84]. How to Navigate the Complexities of Implant Treatment for Patients on Bisphosphates., by Diana Bronstein, DDS, MS, MS; Dmitry Kravchenko, MPH; Cameron Lee, DMD, MD, PhD; MBA; Jon B. Suzuki, DDS,PhD, MBA . Oral health feature, December 2, 2016


DOI: 10.9790/0853-1908162129 www.iosrjournal.org 29 | Page